Azodicarbonamide
The MAK Collection for Occupational Health and Safety · 2026 · 3 (3)
DOI: 10.34865/mb12377e6318_w ↗Kurz gefasst
Fachartikel in der Zeitschrift The MAK Collection for Occupational Health and Safety, 2026. Verfasst von Hartwig und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has evaluated azodicarbonamide [123‐77‐3] to derive a maximum concentration at the workplace (MAK value), considering all toxicological endpoints. Available publications and unpublished study reports are described in detail. The critical effect is the occurrence of reactions in the airways in exposed workers. In the view of the Commission, the present inhalation studies in animals are not appropriate for the derivation of a MAK value as human airways are probably more sensitive than rodent airways. The workplace investigations show no clear correlation of exposure and frequency of respiratory symptoms. Nevertheless, from the NOAEC of 36 µg/m3 for lung function measurements in a small group of injection‐molding workers in the plastics industry, a MAK value of 20 µg/m3 I is established. Due to the incomplete information on the relevant exposure scenario and the uncertainty regarding first occurrence of workplace related symptoms, this value should be considered as preliminary. As local effects are critical, azodicarbonamide is assigned to Peak Limitation Category I and the default excursion factor of 1 is designated. Since developmental toxicity studies are not available, Pregnancy Risk Group D is assigned. There are no carcinogenicity studies and azodicarbonamide is not regarded as germ cell mutagen. Skin contact is not expected to contribute significantly to systemic toxicity. The metabolism of azodicarbonamide and its reactivity do not point to stable protein binding in vivo and therefore, skin or respiratory sensitization is unlikely. Clear‐cut clinical findings or positive results from animal studies on skin sensitization are not available, but the negative results in experimental animals are difficult to evaluate due to the low solubility of the compound. Although azodicarbonamide affects the respiratory tract in several case reports with positive bronchial provocation tests, sensitization by a known mechanism is not adequately verified. Additionally, it appears questionable whether a mono‐causal relationship of respiratory symptoms and azodicarbonamide exposure can really be assumed. In conclusion, a sensitizing effect of azodicarbonamide is not sufficiently proven. Completed: March 22, 2017
Schlagwörter
Zitieren
APA
Hartwig, Andrea, & Commission, M. (2026). Azodicarbonamide. The MAK Collection for Occupational Health and Safety, 3(3). https://doi.org/10.34865/mb12377e6318_w
Vancouver
Hartwig, Andrea, Commission M. Azodicarbonamide. The MAK Collection for Occupational Health and Safety. 2026;3(3). doi:10.34865/mb12377e6318_w
BibTeX
@article{Hartwig2026,
author = {Hartwig and Andrea and Commission, MAK},
title = {Azodicarbonamide},
journal = {The MAK Collection for Occupational Health and Safety},
year = {2026},
volume = {3},
number = {3},
doi = {10.34865/mb12377e6318_w}
}
EUVIMED